Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BPI 2358 (Plinabulin) is a potent dendritic cell maturation agent, which is being evaluated in combination with pembrolizumab plus etoposide/platinum for the treatment of small cell lung cancer extensive stage.
Lead Product(s): Plinabulin,Pembrolizumab,Etoposide
Therapeutic Area: Oncology Product Name: BPI 2358
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
ST-00937, a new chemical entity (NCE) molecular glue that has already achieved IND Candidate status and will be advanced for the treatment of cancers in SEED’s first IND filing, as early as 2024.
Lead Product(s): ST-00937
Therapeutic Area: Oncology Product Name: ST-00937
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
BPI-2358 (plinabulin) triggers the release of the immune defense protein, GEF-H1, which leads to a durable anticancer benefit due to the maturation of dendritic cells resulting in the activation of tumor antigen-specific T-cells to target cancer cells.
Lead Product(s): Plinabulin,Docetaxel,Pembrolizumab
Therapeutic Area: Oncology Product Name: BPI-2358
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
BPI-2358 (Plinabulin), BeyondSpring’s lead asset, is a selective immunomodulating microtubule-binding agent, which is a potent antigen presenting cell (APC) inducer that is being developed as an anticancer agent.
Lead Product(s): Plinabulin,Docetaxel
Therapeutic Area: Hematology Product Name: BPI-2358
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
Plinabulin (BPI-2358) exerts early-onset of action in the prevention of chemotherapy-induced neutropenia (CIN) by boosting the number of hematopoietic stem/progenitor cells (HSPCs).
Lead Product(s): Plinabulin,Pegfilgrastim
Therapeutic Area: Hematology Product Name: BPI-2358
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Plinabulin triggers the release of the immune defense protein, GEF-H1, which leads to two distinct effects: first is a durable anticancer benefit due to the maturation of dendritic cells resulting in the activation of tumor antigen-specific T-cells to target cancer cells.
Lead Product(s): Plinabulin,Pegfilgrastim
Therapeutic Area: Oncology Product Name: BPI-2358
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
Plinabulin (BPI-2358) in combination with docetaxel (DP) showed statistically significant overall survival improvements compared to docetaxel alone (D) for the ITT population (DP: n=278; D: n=281).
Lead Product(s): Plinabulin,Pegfilgrastim
Therapeutic Area: Hematology Product Name: BPI-2358
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
Plinabulin is a first-in-class selective immunomodulating microtubule-binding agent (SIMBA) with potential chemotherapy-induced neutropenia (CIN) prevention and anticancer benefits.
Lead Product(s): Plinabulin,Pegfilgrastim
Therapeutic Area: Oncology Product Name: BPI-2358
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
Plinabulin is a selective immunomodulating microtubule-binding agent (SIMBA), which triggers the release of the immune defense protein, GEF-H1. The plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data.
Lead Product(s): Plinabulin,Pegfilgrastim,Docetaxel
Therapeutic Area: Oncology Product Name: BPI-2358
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2021
Details:
DUBLIN-3 Phase 3 registrational trial of its first-in-class lead asset, plinabulin, in combination with docetaxel used for the treatment of 2nd/3rd line NSCLC patients with EGFR wild type. Plinabulin is a selective immunomodulating microtubule-binding agent.
Lead Product(s): Plinabulin,Docetaxel
Therapeutic Area: Oncology Product Name: BPI-2358
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2021